

Serial No.: Not yet obtained  
Filed: Herewith  
Preliminary Amendment

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### **Listing of Claims**

Claims 1-77 (canceled)

Claim 78 (new): A method of killing a cancer cell that expresses a polypeptide comprising:  
(a) the amino acid sequence shown in SEQ ID NO:9; or  
(b) an amino acid sequence encoded by a nucleotide sequence comprising the nucleotide sequence shown in SEQ ID NO:4, said method comprising contacting said cancer cell with an antibody that binds to said polypeptide on said cancer cell, thereby killing said cancer cell.

Claim 79 (new): The method of Claim 78, wherein said antibody is a monoclonal antibody.

Claim 80 (new): The method of Claim 78, wherein said antibody is an antibody fragment.

Claim 81 (new): The method of Claim 78, wherein said antibody is a chimeric or a humanized antibody.

Claim 82 (new): The method of Claim 78, wherein said antibody is conjugated to a growth inhibitory agent.

Claim 83 (new): The method of Claim 78, wherein said antibody is conjugated to a cytotoxic agent.

Serial No.: Not yet obtained  
Filed: Herewith  
Preliminary Amendment

Claim 84 (new): The method of Claim 83, wherein said cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

Claim 85 (new): The method of Claim 83, wherein the cytotoxic agent is a toxin.

Claim 86 (new): The method of Claim 85, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

Claim 87 (new): The method of Claim 85, wherein the toxin is a maytansinoid.

Claim 88 (new): The method of Claim 78, wherein said antibody is produced in bacteria.

Claim 89 (new): The method of Claim 78, wherein said antibody is produced in CHO cells.

Claim 90 (new): The method of Claim 78, wherein said cancer cell is further exposed to radiation treatment or a chemotherapeutic agent.

Claim 91 (new): The method of Claim 78, wherein said cancer cell is a prostate cancer cell.

Claim 92 (new): The method of Claim 78, wherein said cancer cell overexpresses said polypeptide as compared to a normal cell of the same tissue origin.